NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $2,629,000.80 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 100,728 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80. Following the transaction, the insider now directly owns 10,908,502 shares of the company’s stock, valued at approximately $284,711,902.20. The trade was a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Price Performance

NAMS stock traded up $0.04 during mid-day trading on Friday, reaching $25.50. The company had a trading volume of 1,026,266 shares, compared to its average volume of 378,655. The firm has a 50 day moving average of $21.16 and a 200 day moving average of $18.90. NewAmsterdam Pharma has a 12 month low of $10.50 and a 12 month high of $27.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma during the 2nd quarter valued at $38,000. Quarry LP increased its stake in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after buying an additional 6,247 shares during the period. Barclays PLC increased its stake in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the period. Bellevue Group AG bought a new stake in shares of NewAmsterdam Pharma in the third quarter valued at about $128,000. Finally, XTX Topco Ltd purchased a new stake in NewAmsterdam Pharma in the third quarter worth about $187,000. Institutional investors own 89.89% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on NAMS shares. Piper Sandler restated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Scotiabank boosted their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Buy” and a consensus target price of $36.20.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.